REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Real-Time Price · USD
9.03
-0.23 (-2.48%)
At close: Sep 17, 2025, 4:00 PM EDT
9.21
+0.18 (1.99%)
After-hours: Sep 17, 2025, 5:08 PM EDT
-2.48%
Market Cap456.14M
Revenue (ttm)155.78M
Net Income (ttm)-175.57M
Shares Out 50.51M
EPS (ttm)-3.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume295,861
Open9.23
Previous Close9.26
Day's Range8.99 - 9.50
52-Week Range5.04 - 13.48
Beta1.17
AnalystsStrong Buy
Price Target28.50 (+215.62%)
Earnings DateNov 5, 2025

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2015
Employees 353
Stock Exchange NASDAQ
Ticker Symbol RGNX
Full Company Profile

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $28.5, which is an increase of 215.62% from the latest price.

Price Target
$28.5
(215.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major un...

8 days ago - Seeking Alpha

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Curran Simpson - President, CEO & Director Steve Pakola - Exec...

9 days ago - Seeking Alpha

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential as a gene therapy. Late-stage Sura-vec trials...

11 days ago - Seeking Alpha

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II >80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain ...

12 days ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , Aug. 28, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference 1x1 Inves...

20 days ago - PRNewsWire

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.'s RGNX Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysacc...

4 weeks ago - Benzinga

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approved Commercial launch plans ...

4 weeks ago - PRNewsWire

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.

5 weeks ago - Seeking Alpha

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous gui...

5 weeks ago - PRNewsWire

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiated New Phase II ALTITUDE ® trial data demonstrate a durable safety and efficac...

5 weeks ago - PRNewsWire

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

ROCKVILLE, Md. , July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 7, at 8:00 a.m.

6 weeks ago - PRNewsWire

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation in...

2 months ago - PRNewsWire

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA d...

3 months ago - Seeking Alpha

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.

3 months ago - Benzinga

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Bio...

3 months ago - PRNewsWire

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.

3 months ago - PRNewsWire

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) a...

4 months ago - PRNewsWire

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.

4 months ago - PRNewsWire

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chie...

4 months ago - Seeking Alpha

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS II Partner Nippon Shinyaku to lead commercialization upon potentia...

4 months ago - PRNewsWire

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025  Additional Phase I/II functional data expected 1H 2...

4 months ago - PRNewsWire

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

ROCKVILLE, Md. , May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New...

4 months ago - PRNewsWire

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m.

5 months ago - PRNewsWire

5 Reasons To Buy Regenxbio Right Now

Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, wit...

6 months ago - Seeking Alpha

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% comp...

6 months ago - PRNewsWire